These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 2194280)

  • 1. The renin angiotensin system in diabetes mellitus. A physiological and therapeutic study.
    Björck S
    Scand J Urol Nephrol Suppl; 1990; 126():1-51. PubMed ID: 2194280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE-inhibition and renoprotection in early diabetic nephropathy. Response to enalapril acutely and in long-term combination with conventional antihypertensive treatment.
    Pedersen MM; Christensen CK; Hansen KW; Christiansen JS; Mogensen CE
    Clin Invest Med; 1991 Dec; 14(6):642-51. PubMed ID: 1665407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
    Dzau VJ
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of angiotensin II in diabetic nephropathy.
    Kennefick TM; Anderson S
    Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.
    Björck S; Blohmé G; Sylvén C; Mulec H
    Nephrol Dial Transplant; 1997; 12 Suppl 2():67-70. PubMed ID: 9269704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
    Price DA; De'Oliveira JM; Fisher ND; Williams GH; Hollenberg NK
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):348-55. PubMed ID: 10232494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
    Erman A; Boner G; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N; Amuchastegui CS; Malanchini B; Bertani T; Remuzzi G
    Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes, nephropathy, and the renin system.
    Hollenberg NK
    J Hypertens Suppl; 2006 Mar; 24(1):S81-7. PubMed ID: 16601578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal sensitivity to angiotensin II in type 1 diabetes.
    Björck S; Aurell M; Bresäter LE; Herlitz H; Welin L; Wikstrand J
    Scand J Urol Nephrol; 1990; 24(4):267-73. PubMed ID: 2274750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats.
    Komers R; Schutzer W; Xue H; Oyama TT; Lindsley JN; Anderson S
    Transl Res; 2007 Dec; 150(6):343-9. PubMed ID: 18022596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased aldosterone levels in a model of type 2 diabetes mellitus.
    Fredersdorf S; Endemann DH; Luchner A; Heitzmann D; Ulucan C; Birner C; Schmid P; Stoelcker B; Resch M; Muders F; Riegger GA; Weil J
    Exp Clin Endocrinol Diabetes; 2009 Jan; 117(1):15-20. PubMed ID: 18726873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.